Candel Therapeutics Inc.

Clinical-stage biopharma developing off-the-shelf viral immunotherapies for solid tumors. Lead asset CAN-2409 (aglatimagene besadenovec), an adenovirus-delivered HSV-tk gene therapy combined with valacyclovir, met the primary endpoint in a Phase 3 prostate cancer trial with BLA submission planned for Q4 2026, and is advancing into pivotal Phase 3 in NSCLC. HSV-based CAN-3110 is in Phase 1b for recurrent high-grade glioma.